Sigyn Therapeutics (SIGY) Liabilities and Shareholders Equity (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Liabilities and Shareholders Equity of $135571.0 for Q3 2025, up 161.93% sequentially from $51759.0 in Q2 2025, and down 68.28% YoY from $427438.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $135571.0 in Q3 2025.
- Quarterly Liabilities and Shareholders Equity fell 68.28% year-over-year to $135571.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $645358.0 (down 53.66% YoY) and the FY2024 annual result came in at $213719.0, down 33.59% from the prior year.
- Liabilities and Shareholders Equity grew to $135571.0 in Q3 2025 per SIGY's latest filing, from $51759.0 in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $2.0 million in Q2 2021 and troughed at $51759.0 in Q2 2025.
- A 5-year average of $512559.2 and a median of $362273.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity soared 219.99% in 2021, then slumped 83.83% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $710259.0 in 2021, then tumbled by 53.13% to $332879.0 in 2022, then slipped by 3.33% to $321806.0 in 2023, then plunged by 33.59% to $213719.0 in 2024, then sank by 36.57% to $135571.0 in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $135571.0, $51759.0, and $244309.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 135,571.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 135,571.00 |
| Jun 30, 2025 | 51,759.00 |
| Mar 31, 2025 | 244,309.00 |
| Dec 31, 2024 | 213,719.00 |
| Sep 30, 2024 | 427,438.00 |
| Jun 30, 2024 | 320,165.00 |
| Mar 31, 2024 | 323,295.00 |
| Dec 31, 2023 | 321,806.00 |
| Sep 30, 2023 | 387,223.00 |
| Jun 30, 2023 | 361,817.00 |
| Mar 31, 2023 | 660,447.00 |
| Dec 31, 2022 | 332,879.00 |
| Sep 30, 2022 | 362,273.00 |
| Jun 30, 2022 | 395,908.00 |
| Mar 31, 2022 | 447,414.00 |
| Dec 31, 2021 | 710,259.00 |
| Sep 30, 2021 | 1.44 Mn |
| Jun 30, 2021 | 1.99 Mn |
| Mar 31, 2021 | 608,960.00 |
| Dec 31, 2020 | 694,082.00 |